Key Takeaways:
- AbbVie surged 11% in a week, adding $43 billion in market value.
- The $10.9 billion Apogee acquisition strengthens its immunology pipeline.
- Skyrizi and Rinvoq secured new regulatory approvals in the US and EU.
Back
AbbVie adds $43B in market cap as acquisitions and approvals drive rally
AbbVie gained 11% in the past week, adding $43 billion in market value as acquisitions and regulatory approvals boosted investor confidence.
"The Apogee acquisition strengthens our immunology franchise for the next decade and beyond," AbbVie said in announcing the $10.9 billion deal.
The transaction, which adds clinical-stage biotech Apogee Therapeutics to AbbVie's portfolio, is designed to reinforce the company's competitive position against Sanofi and Regeneron's blockbuster immunology therapy Dupixent. The deal also addresses one of the market's biggest concerns: how AbbVie plans to sustain growth once Skyrizi and Rinvoq eventually mature.
The rally followed several positive developments for AbbVie's existing drug portfolio. The US Food and Drug Administration approved Skyrizi for pediatric patients with moderate-to-severe plaque psoriasis, while the European Commission cleared the drug for the same indication. Separately, a European Medicines Agency committee recommended Rinvoq for alopecia areata and vitiligo, two additional autoimmune indications.
The $43 billion gain reflects growing confidence that AbbVie has successfully navigated the loss of exclusivity for Humira, which once generated more than half of total revenue. The company expects total revenue to rise about 10% in 2026 and high single-digit growth through 2029, with no significant patent expirations for the rest of the decade.
Beyond immunology, AbbVie's neuroscience and oncology units are gaining traction. Vyalev, the Parkinson's disease therapy launched last year in the US, is expected to surpass $1 billion in annual sales. In oncology, the company secured approval for Decnupaz to treat blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive blood cancer. The oncology portfolio remains anchored by Venclexta and Elahere.
The stock closed at a 52-week high of $253.35 on June 26, joining Eli Lilly, Johnson & Johnson and Biogen in reaching new highs as the broader biotech sector rallied. The SPDR S&P Biotech ETF gained 16.4% in the past month, while the iShares Biotechnology ETF rose 10.6%.
The rally shows that AbbVie's post-Humira growth strategy is gaining credibility with investors. The next event for investors will be the company's second-quarter earnings report, where they will look for updated guidance on Skyrizi and Rinvoq sales trajectories.
This article is for informational purposes only and does not constitute investment advice.
[1] What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?[2] What sparked the $43B jump in AbbVie's market cap in the past week?[3] Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities[4] Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs - Zacks Investment Research
